RegulatoryCompany release

Acumen to report Phase 2 ALTITUDE-AD sabirnetug data in November

🇺🇸 Acumen Pharmaceuticals, Inc. (ABOS) · Mon 26 Oct 2026

Acumen Pharmaceuticals expects topline results from its 542-patient Phase 2 trial of sabirnetug in early Alzheimer's disease next month, with ARIA rates among the safety measures.

Acumen Pharmaceuticals said on 26 October 2026 that it expects to announce topline results from its Phase 2 ALTITUDE-AD trial of sabirnetug in November 2026. The study enrolled 542 patients with early Alzheimer's disease.

The readout will cover the primary endpoint, the integrated Alzheimer's Disease Rating Scale (iADRS), along with secondary endpoints and safety measures. Safety data will include rates of amyloid-related imaging abnormalities (ARIA).

The company also said it is targeting an investigational new drug (IND) application in mid-2027 for its lead candidate in the Enhanced Brain Delivery programme. No further details on that candidate were provided in the material available.

On finances, Acumen reported cash of $78.6 million, which it projects will last into early 2027. The company did not provide further detail in the information available.

What it means for your team

  • Regulatory and PV teams tracking amyloid-targeting antibodies should watch the ARIA rates in the November readout, as they are a key safety measure for the class.
  • Market-access analysts will get a first view of iADRS efficacy data for sabirnetug in early Alzheimer's disease, though the announcement gives no results yet.
  • The mid-2027 IND target for the Enhanced Brain Delivery candidate signals a possible next-generation pipeline step, but no timeline beyond the filing has been stated.
  • The cash runway into early 2027 means the data and any financing or partnering decisions are closely linked in timing.

Company's press release (SEC filing): Acumen Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Acumen Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →